within Pharmacolibrary.Examples;
model PK_1C_LithiumCarbonate
  extends Pharmacolibrary.Examples.PKOneCompartmentModelPeriodic(periodicDose(
      firstAdminTime=3600,
      adminPeriod=86400,
      adminMass=0.0015,                                                                                                                       doseCount = 10,
      adminDuration=7200,                                                                                                                                                           F = 1), central(V = 0.225), elim(CL = 2.616666666666667e-6));
    parameter Pharmacolibrary.Types.MassConcentration Cmin = 0.004 "Minimal therapeutic level";
    parameter Pharmacolibrary.Types.MassConcentration Cmax = 0.01 "Maximal therapeutic level";
    parameter Pharmacolibrary.Types.MassConcentration Ctox = 0.013 "Toxicity risk level";
    parameter Pharmacolibrary.Types.MassConcentration Clab = 0.008 "Laboratory level";

equation

annotation(
    experiment(StartTime = 0, StopTime = 864000, Tolerance = 1e-09, Interval = 1),
  Documentation(info = "<html><head></head><body>Pharmacokinetic of <b>Lithium</b>&nbsp;administered as Lithium Carbonate&nbsp;- single compartment model example with parameter values of lithium, dosage 1500 mg administered orally every 24h with bioavailability 1.<div><br></div><div><strong data-start=\"0\" data-end=\"11\" data-is-only-node=\"\">Lithium</strong> is a monovalent metal cation (Li<sup>+</sup>) and is classified pharmacologically as a mood-stabilizing agent. It is not an organic compound like most drugs but a simple inorganic ion, typically administered as lithium carbonate (Li<sub>2</sub>CO<sub>3</sub>) orlithium citrate. Its exact mechanism of action is not fully understood, but it is thought to modulate intracellular signaling pathways, including second messengers like inositol phosphate and glycogen synthase kinase-3 (GSK-3), which affect neuronal excitability and mood regulation. Lithium is absorbed well orally, is not metabolized, and is excreted unchanged by the kidneys. Pharmacokinetic may follow 1-compartment model(this example) or 2-compartment model.</div><div><span data-start=\"245\" data-end=\"282\">Common side effects include <span data-start=\"497\" data-end=\"507\">tremor</span>, <span data-start=\"509\" data-end=\"529\">increased thirst</span>, <span data-start=\"531\" data-end=\"543\">polyuria</span>, and <span data-start=\"549\" data-end=\"564\">weight gain</span>. Toxicity can occur easily due to a <span data-start=\"601\" data-end=\"629\">narrow therapeutic index</span> and may cause <span data-start=\"644\" data-end=\"654\">nausea</span>, <span data-start=\"656\" data-end=\"668\">vomiting</span>, <span data-start=\"670\" data-end=\"683\">confusion</span>, <span data-start=\"685\" data-end=\"697\">seizures</span>, or <span data-start=\"702\" data-end=\"725\">cardiac arrhythmias</span>. Renal and thyroid function must be monitored regularly.</span></div><div><br></div><div><div><b>Simulation </b>of 10d, drug administered every day, therapeutic level are between Cmin adn Cmax, toxic level above Ctox:</div><div>&nbsp;
<img src=\"modelica://Pharmacolibrary/Resources/Icons/pk_1c_li_sim.png\"></div><div><br></div><div><br></div><div><b>References:</b></div><div>[1] Wen, Jinhua, et al. \"A review for lithium: pharmacokinetics, drug design, and toxicity.\" CNS &amp; Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS &amp; Neurological Disorders) 18.10 (2019): 769-778.</div></div></body></html>"));
end PK_1C_LithiumCarbonate;
